Pharmasimple SA (EPA:ALPHS) Is Expected To Breakeven

January 28, 2020

Pharmasimple SA's (EPA:ALPHS): Pharmasimple SA operates a Website for medicines, cosmetics, and food supplements in Belgium and France. The €17m market-cap posted a loss in its most recent financial year of -€2.4m and a latest trailing-twelve-month loss of -€2.4m shrinking the gap between loss and breakeven. As path to profitability is the topic on ALPHS’s investors mind, I’ve decided to gauge market sentiment. In this article, I will touch on the expectations for ALPHS’s growth and when analysts expect the company to become profitable.

See our latest analysis for Pharmasimple

According to the industry analysts covering ALPHS, breakeven is near. They expect the company to post a final loss in 2020, before turning a profit of €600k in 2021. So, ALPHS is predicted to breakeven approximately a few months from now. What rate will ALPHS have to grow year-on-year in order to breakeven on this date? Using a line of best fit, I calculated an average annual growth rate of 102%, which is rather optimistic! If this rate turns out to be too aggressive, ALPHS may become profitable much later than analysts predict.

ENXTPA:ALPHS Past and Future Earnings, January 29th 2020

Given this is a high-level overview, I won’t go into details of ALPHS’s upcoming projects, though, keep in mind that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

One thing I would like to bring into light with ALPHS is its debt-to-equity ratio of over 2x. Typically, debt shouldn’t exceed 40% of your equity, which in ALPHS’s case, it has significantly overshot. Note that a higher debt obligation increases the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on ALPHS, so if you are interested in understanding the company at a deeper level, take a look at ALPHS’s company page on Simply Wall St. I’ve also compiled a list of key factors you should look at:

Valuation: What is ALPHS worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether ALPHS is currently mispriced by the market.
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Pharmasimple’s board and the CEO’s back ground.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.